ArticleTranslational lung cancer research2026
Association between patient-reported outcomes and pathological response in neoadjuvant chemoimmunotherapy-a post hoc analysis of the TD-FOREKNOW trial.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemoimmunotherapy improves pathological outcomes and survival in resectable non-small cell lung cancer (NSCLC), but its effect on quality of life and the association between pathological response and patient-reported outcomes (PROs) are not well established. This analysis from phase II of the TD-FOREKNOW trial explores the preliminary relationship between pathologic complete response (pCR) and PROs. Methods: In this randomized phase 2 trial, patients with stage IIIA-IIIB (T3N2) NSCLC received camrelizumab plus chemotherapy or chemotherapy alone followed by surgery. PROs [global health status/quality of life (GHS/QoL), cough, dyspnea, hemoptysis] were compared between pCR and non-pCR groups using change-from-baseline analyses. Results: A total of 94 patients were randomized. Among 40 patients who received camrelizumab plus chemotherapy followed by surgery and completed ≥1 PRO assessment, 14 achieved pCR and 26 did not. GHS/QoL scores declined during neoadjuvant therapy but recovered postoperatively in both groups. During neoadjuvant treatment, pCR patients showed significantly greater improvement in cough [least square (LS) mean difference: -18.2; 95% confidence interval (CI): -33.0 to -3.5; P=0.02] and dyspnea (-21.3; 95% CI -38.3 to -4.3; P=0.02) compared to non-pCR patients. Conclusions: These findings suggest that pCR is associated with superior PROs, highlighting its potential as a marker for patient-centered benefits beyond survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.